Stoke Therapeutics Stock News

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) hit a new 52-week low during mid-day trading on Monday following insider selling activity. The stock traded as low as $18.92 and last traded at $19.49, with a volume of 903 shares trading hands. The stock had previously closed at $23.85. Specifically, COO Huw M. Nash sold 1,900 shares [] The post Stoke Therapeutics (NASDAQ:STOK) Sets New 1-Year Low After Insider Selling appeared first on ETF Daily News .

Stoke Therapeutics, Inc. (NASDAQ:STOK) COO Huw M. Nash sold 5,700 shares of the businesss stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $24.44, for a total value of $139,308.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available []

The study results are early and far from conclusive, but show the potential for a therapy to target the underlying genetic cause of disease.

An experimental drug from Stoke Therapeutics reduced the frequency of convulsive seizures in children with a rare form of epilepsy called Dravet syndrome, the company said.

Stoke Therapeutics (NASDAQ:STOK) was upgraded by equities researchers at JPMorgan Chase & Co. from a neutral rating to an overweight rating in a research report issued to clients and investors on Monday, Price Targets.com reports. The brokerage presently has a $41.00 target price on the stock. JPMorgan Chase & Co.s price target points to a []

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) gapped up before the market opened on Monday . The stock had previously closed at $27.80, but opened at $29.49. Stoke Therapeutics shares last traded at $30.01, with a volume of 971 shares changing hands. A number of research firms have weighed in on STOK. HC Wainwright reaffirmed a []

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that five abstracts related to the Companys work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2021 Annual Meeting, taking place December 3 7, 2021 in Chicago. At Stoke, our goal is to develop the first medicine to target the

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received an average rating of Buy from the eight research firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have issued []

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression wi

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression wi

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression wi

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression w